Recombinant granulocyte growth factors in the management of HIV-related neoplasms: personal experience (Meeting abstract).

Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Recombinant granulocyte growth factors in the management of HIV-related neoplasms: personal experience (Meeting abstract).

Molecular Biology of Hematopoiesis, 8th Symposium. July 9-13, 1993, Basel, Switzerland, p. 60, 1993.. Unique Identifier : AIDSLINE ICDB/95699340
Torresin A; Guida B; Crisalli MP; Piersantelli N; Infectious Diseases Dept., Galliera Hosp., Genoa, Italy

Abstract: The aim of our study was to assess the role for recombinant granulocyte growth factors (rG-CSF) in the management of HIV-related malignancies. We treated with chemo and/or radiotherapy 6 patients, all males, mean age 35 years, HIV infected, belonging in the IV class of CDC staging classification, for the following neoplasms: 1 Hodgkin's disease, 3 non-Hodgkin's lymphomas, 1 seminoma and 1 Kaposi's sarcoma. In all of them rG-CSF was administered during the cycles (5 ug/kg/day sc) and maintained in the intervals only when necessary. All patients completed therapy but for 1 who had progressed and died while being treated. One achieved complete remission, 2 partial remission and the remaining 3 progressed. The lowest leukocyte counts averaged 0.6 x 10(9)/L for a maximum of 2 days. No infectious or febrile complication was recorded, nobody required prophylactic antibiotic or antifungal therapy. Life quality was altogether improved. Although insufficient to draw any conclusion on its efficacy upon survival and disease outcome, our experience with rG-CSF was positive in that it succeeded in preventing drug-induced myelosuppression and its infectious consequences in our heavily compromised patients.

Keywords: Acquired Immunodeficiency Syndrome/*COMPLICATIONS Adult Granulocyte Colony-Stimulating Factor/*THERAPEUTIC USE Hodgkin's Disease/COMPLICATIONS/*THERAPY Human Leukocyte Count Lymphoma, Non-Hodgkin's/COMPLICATIONS/*THERAPY Male Recombinant Proteins/THERAPEUTIC USE Remission Induction Sarcoma, Kaposi's/ETIOLOGY/*THERAPY Seminoma/COMPLICATIONS/*THERAPY ABSTRACT
950228
M9521044

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .